BRAF and biliary tract neoplasm: In Rare Oncology Agnostic Research (ROAR) basket trial targeting solid tumors with BRAF V600E, 43 patients with BRAF V600E-mutated biliary tract cancer were enrolled and dabrafenib (BRAF inhibitor) plus trametinib (MEK inhibitor) showed 47% of ORR and 14 months of median OS [59].